Cybin Streamlines Organization As It Focuses On Clinical-Stage: Here's How The Market Responded

Cybin Inc. CYBN CYBN announced Thursday a streamlining plan aimed at maximizing the company’s operating efficiency and allowing it to focus on critical clinical trials.

The biopharmaceutical company has released approximately 15% of its workforce that previously held roles that were not of a clinical priority or were not directly involved with any of the company’s clinical trial initiatives. As a result of the headcount reductions, Cybin expects to generate cost savings from reducing operating expenses.

Based on anticipated cost savings from the streamlining exercise and Cybin’s ongoing and previously announced $35 million at-the-market (“ATM”) equity program, management believes the company will be better positioned for both near-term and long-term success. Cybin anticipates these cost savings will result in a decrease in its historical annual cash burn rate by millions of dollars, while it continues to push forward on all core clinical initiatives.

“The Company has made the prudent decision to evaluate every role within its workforce, including whether certain tasks could be performed more efficiently while ensuring that the Company’s core clinical activities continue to be robustly supported and resourced. We appreciate the significant contributions of our employees and the hard work they performed for the Company and understand the impact that this difficult decision has on them. We are committed to maintaining a lean organization and will continue to make clinical trial execution in support of our proprietary molecules our top priority” stated Doug Drysdale, chief executive officer of Cybin.

Price Action

Cybin shares were trading 10.74% lower at $0.46 per share at the time of writing Thursday morning.

Benzinga Cannabis Capital Conference Is Back!

The most successful cannabis business event in the world, the Benzinga Cannabis Capital Conference, returns to Miami for its 16th edition.
This is the place where DEALS GET DONE, where money is raised, M&A starts, and companies meet investors and key partners. Join us at the Fontainebleau Miami Beach Hotel in Florida on April 11-12. Don’t miss out.
Secure your tickets now. Prices will surge very soon.

Photo: Benzinga edit with image by Raimundo79 and Sergey Nivens on Shutterstock



Market News and Data brought to you by Benzinga APIs
Posted In: CannabisNewsPsychedelicsMarketsDoug Drysdalepremiumwhy it is moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on – Prices will increase very soon!